Diagnostics
Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately-held companies in the region with an earnings increase of more than 2,000 percent over a three-year period.
an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk patients) and show a favorable and distinct treatment strategy for the low and high-risk patients in an interim data analysis.
MDxHealth SA today announces that the New York State Department of Health has approved its SelectMDx test for Prostate Cancer.
Esperion today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in Chicago.
DCN Dx and QIAGEN Lake Constance announced today that Rapid Pathogen Screening, Inc. (RPS) was the winner of the first $10,000 Innovation Award at the Advanced Lateral Flow Course.
Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products
Epigenomics AG today announced its financial results for the third quarter and the nine months 2018 ending September 30.
Real-world study shows that SelectMDx helps urologists more confidently determine the need for an initial prostate biopsy
Oxford Immunotec Global PLC today announced that it plans to release third quarter 2018 financial results prior to market open on Friday, November 9, 2018.
Company to Participate in USA Corporate Executive Office Program
PRESS RELEASES